Regeneron to buy 23andMe out of bankruptcy for $256 million

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company’s privacy policies.

Submit a Comment

Your email address will not be published. Required fields are marked *

Chat with us.

Hi there! How can I help you? ?